Health Catalyst, Inc. (NASDAQ:HCAT) Shares Sold by Fred Alger Management LLC

Fred Alger Management LLC lessened its stake in Health Catalyst, Inc. (NASDAQ:HCAT - Free Report) by 55.7% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 372,865 shares of the company's stock after selling 469,644 shares during the period. Fred Alger Management LLC owned about 0.61% of Health Catalyst worth $2,636,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. First Light Asset Management LLC lifted its position in shares of Health Catalyst by 22.0% during the 4th quarter. First Light Asset Management LLC now owns 5,241,121 shares of the company's stock worth $37,055,000 after buying an additional 944,631 shares during the last quarter. Impax Asset Management Group plc grew its holdings in shares of Health Catalyst by 7.7% during the fourth quarter. Impax Asset Management Group plc now owns 2,750,000 shares of the company's stock worth $19,442,000 after buying an additional 195,525 shares during the last quarter. Daventry Group LP increased its position in Health Catalyst by 3.8% in the 4th quarter. Daventry Group LP now owns 2,509,480 shares of the company's stock valued at $17,742,000 after acquiring an additional 91,878 shares during the period. Alyeska Investment Group L.P. raised its stake in Health Catalyst by 74.4% during the 4th quarter. Alyeska Investment Group L.P. now owns 2,019,380 shares of the company's stock valued at $14,277,000 after acquiring an additional 861,150 shares during the last quarter. Finally, Kennedy Capital Management LLC lifted its position in Health Catalyst by 42.7% during the 4th quarter. Kennedy Capital Management LLC now owns 1,891,000 shares of the company's stock worth $13,369,000 after acquiring an additional 565,445 shares during the period. Hedge funds and other institutional investors own 85.00% of the company's stock.

Analyst Ratings Changes

A number of research firms recently weighed in on HCAT. Stifel Nicolaus lifted their price objective on shares of Health Catalyst from $5.00 to $5.50 and gave the company a "hold" rating in a research report on Thursday, May 8th. Citigroup lowered their target price on shares of Health Catalyst from $7.00 to $6.50 and set a "buy" rating on the stock in a report on Friday, April 25th. Stephens reduced their price objective on shares of Health Catalyst from $7.00 to $5.00 and set an "equal weight" rating for the company in a research report on Thursday, March 6th. Evercore ISI lowered Health Catalyst from an "outperform" rating to an "inline" rating in a report on Wednesday, April 9th. Finally, KeyCorp dropped their target price on Health Catalyst from $7.00 to $5.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 16th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $8.00.

Health Catalyst Price Performance

HCAT stock traded down $0.23 during midday trading on Tuesday, hitting $4.29. 631,355 shares of the stock were exchanged, compared to its average volume of 600,940. The stock's 50-day moving average price is $4.13 and its 200-day moving average price is $5.89. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41. The stock has a market cap of $301.21 million, a price-to-earnings ratio of -3.18 and a beta of 1.56. Health Catalyst, Inc. has a fifty-two week low of $3.56 and a fifty-two week high of $9.24.

Insider Activity

In related news, COO Daniel Lesueur sold 16,902 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $4.52, for a total value of $76,397.04. Following the transaction, the chief operating officer now owns 216,250 shares in the company, valued at approximately $977,450. This trade represents a 7.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Linda Llewelyn sold 6,441 shares of the business's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $5.43, for a total value of $34,974.63. Following the transaction, the insider now owns 85,819 shares in the company, valued at approximately $465,997.17. This represents a 6.98% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 47,588 shares of company stock worth $217,259 over the last 90 days. 2.50% of the stock is currently owned by corporate insiders.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.